Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

Maria Dêbiec‐Rychter, Raf Sciot, Axel Le Cesne et al. · European Journal of Cancer · 2006 · 899 citations

Medicine, Molecular Genetics, Oncology +14

Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas

Nicolas Girard, Ronglai Shen, Tianhua Guo et al. · Clinical Cancer Research · 2009 · 193 citations · Full text

Medicine, Genetics, Oncology +17

KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas

Chin‐Chen Pan, Paul Chih‐Hsueh Chen, Hung Chiang · The Journal of Pathology · 2004 · 179 citations

Medicine, Oncology, Pathology +17

Immunohistochemical KIT (CD117) Expression in Thymic Epithelial Tumors

Kazuo Nakagawa, Yoshihiro Matsuno, Hideo Kunitoh et al. · CHEST Journal · 2005 · 145 citations

Medicine, Oncology, Pathology +14

Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas

Giuseppe Giaccone, Arun Rajan, Rita Ruijter et al. · Journal of Thoracic Oncology · 2009 · 112 citations · Full text

Medicine, Immunology, Oncology +6